RXR partial agonist produced by side chain repositioning of alkoxy RXR full agonist retains antitype 2 diabetes activity without the adverse effects

Journal of Medicinal Chemistry

Volumn 58, Issue 2, 2015, Pages 912-926

  Kawata, Kohei ^a   Morishita, Ken Ichi ^a   Nakayama, Mariko ^a   Yamada, Shoya ^a,b   Kobayashi, Toshiki ^a   Furusawa, Yuki ^a   Arimoto Kobayashi, Sakae ^a   Oohashi, Toshitaka ^a   Makishima, Makoto ^c   Naitou, Hirotaka ^d   Ishitsubo, Erika ^e   Tokiwa, Hiroaki ^e   Tai, Akihiro ^f   Kakuta, Hiroki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF SHIZUOKA   (Japan)

^e RIKKYO UNIVERSITY   (Japan)

^f PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 [ETHYL (3 ISOBUTOXY 4 ISOPROPYLPHENYL)AMINO]PYRIDINE 3 CARBOXYLIC ACID; 6 [ETHYL (4 ISOBUTOXY 3 ISOPROPYLPHENYL)AMINO]PYRIDINE 3 CARBOXYLIC ACID; ALKYL GROUP; ANTIDIABETIC AGENT; GLUCOSE; HETERODIMER; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; RETINOID X RECEPTOR; RETINOID X RECEPTOR PARTIAL AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COS 1 CELL LINE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; EC50; FEMALE; GENOTOXICITY; GLUCOSE BLOOD LEVEL; HEPATOMEGALY; HEPG2 CELL LINE; HUMAN; HYDROPHOBICITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; WEIGHT CHANGE; AGONISTS; ANIMAL; CHLOROCEBUS AETHIOPS; DIABETES MELLITUS, TYPE 2; INSTITUTE FOR CANCER RESEARCH MOUSE; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DIABETES MELLITUS, TYPE 2; FEMALE; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; RETINOID X RECEPTORS;

EID: 84921449420     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501863r     Document Type: Article

References (51)

1. Yamada, S.; Kakuta, H. Retinoid X receptor ligands: a patent review (2007-2013) Expert Opin. Ther. Pat. 2014, 24, 443-452
2. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H. International Union of Pharmacology. LXIII. Retinoid X receptors Pharmacol. Rev. 2006, 58, 760-772
3. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schiitz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The nuclear receptor superfamily: the second decade Cell 1995, 83, 835-839
4. Shulman, A. I.; Larson, C.; Mangelsdorf, D. J.; Ranganathan, R. Structural determinants of allosteric ligand activation in RXR heterodimers Cell 2004, 116, 417-429
5. Ronald, M.; Evans, D.; Mangelsdorf, D. J. Nuclear receptors, RXR, and the big bang Cell 2014, 157, 255-266
6. Bortolini, M.; Wright, M. B.; Bopst, M.; Balas, B. Examining the safety of PPAR agonists-current trends and future prospects Expert Opin. Drug Saf. 2013, 12, 65-79
7. Schultz, J. R.; Tu, H.; Luk, A.; Repa, J. J.; Medina, J. C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D. J.; Lustig, K. D.; Shan, B. Role of LXRs in control of lipogenesis Genes Dev. 2000, 14, 2831-2838
8. Mitro, N.; Mak, P. A.; Vargas, L.; Godio, C.; Hampton, E.; Molteni, V.; Kreusch, A.; Saez, E. The nuclear receptor LXR is a glucose sensor Nature 2007, 445, 219-223
9. Terasaka, N.; Hiroshima, A.; Koieyama, T.; Ubukata, N.; Morikawa, Y.; Nakai, D.; Inaba, T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice FEBS Lett. 2003, 536, 6-11
10. Schulman, I. G.; Shao, G.; Heyman, R. A. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimers: intermolecular synergy requires only the PPARgamma hormone-dependent activation function Mol. Cell. Biol. 1998, 18, 3483-3494
11. Yoshikawa, T.; Shimano, H.; Amemiya-Kudo, M.; Yahagi, N.; Hasty, A. H.; Matsuzaka, T.; Okazaki, H.; Tamura, Y.; Iizuka, Y.; Ohashi, K.; Osuga, J.; Harada, K.; Gotoda, T.; Kimura, S.; Ishibashi, S.; Yamada, N. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter Mol. Cell. Biol. 2001, 21, 2991-3000
12. Forman, B. M.; Umesono, K.; Chen, J.; Evans, R. M. Unique response pathways are established by allosteric interactions among nuclear hormone receptors Cell 1995, 81, 541-550
13. Shulman, A. I.; Larson, C.; Mangelsdorf, D. J.; Ranganathan, R. Structural determinants of allosteric ligand activation in RXR heterodimers Cell 2004, 116, 417-429
14. Altucci, L.; Leibowitz, M. D.; Ogilvie, K. M.; de Lera, A. R.; Gronemeyer, H. RAR and RXR modulation in cancer and metabolic disease Nature Rev. Drug Discovery 2007, 6, 793-810
15. Pileri, A.; Delfino, C.; Grandi, V.; Pimpinelli, N. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides Immunotherapy 2013, 5, 427-433
16. Mukherjee, R.; Davies, P. J.; Crombie, D. L.; Bischoff, E. D.; Cesario, R. M.; Jow, L.; Hamann, L. G.; Boehm, M. F.; Mondon, C. E.; Nadzan, A. M.; Paterniti, J. R.; Jr.; Heyman, R. A. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists Nature 1997, 386, 407-410
17. Cramer, P. E.; Cirrito, J. R.; Wesson, D. W.; Lee, C. Y.; Karlo, J. C.; Zinn, A. E.; Casali, B. T.; Restivo, J. L.; Goebel, W. D.; James, M. J.; Brunden, K. R.; Wilson, D. A.; Landreth, G. E. ApoE-directed therapeutics rapidly clear ?-amyloid and reverse deficits in AD mouse models Science 2012, 335, 1503-1506
18. McFarland, K.; Spalding, T. A.; Hubbard, D.; Ma, J. N.; Olsson, R.; Burstein, E. S. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinsons disease ACS Chem. Neurosci. 2013, 4, 1430-1438
19. Fujii, S.; Ohsawa, F.; Yamada, S.; Shinozaki, R.; Fukai, R.; Makishima, M.; Enomoto, S.; Tai, A.; Kakuta, H. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation Bioorg. Med. Chem. Lett. 2010, 20, 5139-5142
20. y type 2 diabetes model mice Biol. Pharm. Bull. 2012, 35, 629-633
21. Standeven, A. M.; Thacher, S. M.; Yuan, Y. D.; Escobar, M.; Vuligonda, V.; Beard, R. L.; Chandraratna, R. A. Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents Biochem. Pharmacol. 2001, 62, 1501-1509
22. de Vries-van der Weij, J.; de Haan, W.; Hu, L.; Kuif, M.; Oei, H. L.; van der Hoorn, J. W.; Havekes, L. M.; Princen, H. M.; Romijn, J. A.; Smit, J. W.; Rensen, P. C. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein Endocrinology 2009, 150, 2368-2375
23. Lenhard, J. M.; Lancaster, M. E.; Paulik, M. A.; Weiel, J. E.; Binz, J. G.; Sundseth, S. S.; Gaskill, B. A.; Lightfoot, R. M.; Brown, H. R. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction Diabetologia 1999, 42, 545-554
24. Standeven, A. M.; Escobar, M.; Beard, R. L.; Yuan, Y. D.; Chandraratna, R. A. Mitogenic effect of retinoid X receptor agonists in rat liver Biochem. Pharmacol. 1997, 54, 517-524
25. Sherman, S. I. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma Clin. Lymphoma 2003, 3, 249-252
26. Canan Koch, S. S.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Identification of the first retinoid X, receptor homodimer antagonist J. Med. Chem. 1996, 39, 3229-3234
27. Beard, R. L.; Colon, D. F.; Song, T. K.; Davies, P. J.; Kochhar, D. M.; Chandraratna, R. A. Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid J. Med. Chem. 1996, 39, 3556-3563
28. Nahoum, V.; Pérez, E.; Germain, P.; Rodríguez-Barrios, F.; Manzo, F.; Kammerer, S.; Lemaire, G.; Hirsch, O.; Royer, C. A.; Gronemeyer, H.; de Lera, A. R.; Bourguet, W. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 17323-17328
29. Kakuta, H.; Yakushiji, N.; Shinozaki, R.; Ohsawa, F.; Yamada, S.; Ohta, Y.; Kawata, K.; Nakayama, M.; Hagaya, M.; Fujiwara, C.; Makishima, M.; Uno, S.; Tai, A.; Maehara, A.; Nakayama, M.; Oohashi, T.; Yasui, H.; Yoshikawa, Y. RXR partial agonist CBt-PMN exerts therapeutic effects on type 2 diabetes without the side effects of RXR full agonists ACS Med. Chem. Lett. 2012, 3, 427-432
30. Ohsawa, F.; Yamada, S.; Yakushiji, N.; Shinozaki, R.; Nakayama, M.; Kawata, K.; Hagaya, M.; Kobayashi, T.; Kohara, K.; Furusawa, Y.; Fujiwara, C.; Ohta, Y.; Makishima, M.; Naitou, H.; Tai, A.; Yoshikawa, Y.; Yasui, H.; Kakuta, H. Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1 H -benzotriazole-5-carboxylic acid and structural development to increase potency J. Med. Chem. 2013, 56, 1865-1877
31. Nishimaki-Mogami, T.; Tamehiro, N.; Sato, Y.; Okuhira, K.; Sai, K.; Kagechika, H.; Shudo, K.; Abe-Dohmae, S.; Yokoyama, S.; Ohno, Y.; Inoue, K.; Sawada, J. The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines Biochem. Pharmacol. 2008, 76, 1006-1013
32. Ohsawa, F.; Morishita, K.; Yamada, S.; Makishima, M.; Kakuta, H. Modification at the lipophilic domain of RXR agonists differentially influences activation of RXR heterodimers ACS Med. Chem. Lett. 2010, 1, 521-525
33. Takamatsu, K.; Takano, A.; Yakushiji, N.; Morohashi, K.; Morishita, K.; Matsuura, N.; Makishima, M.; Tai, A.; Sasaki, K.; Kakuta, H. The first potent subtype-selective retinoid X receptor (RXR) agonist possessing a 3-isopropoxy-4-isopropylphenylamino moiety, NEt-3IP (RXRalpha/beta-dual agonist) ChemMedChem 2008, 3, 780-787
34. Davies, P. J.; Berry, S. A.; Shipley, G. L.; Eckel, R. H.; Hennuyer, N.; Crombie, D. L.; Ogilvie, K. M.; Peinado-Onsurbe, J.; Fievet, C.; Leibowitz, M. D.; Heyman, R. A.; Auwerx, J. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity Mol. Pharmacol. 2001, 59, 170-176
35. Takahashi, B.; Ohta, K.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Kagechika, H. Novel retinoid X receptor antagonists: Specific inhibition of retinoid synergism in RXR-RAR heterodimer actions J. Med. Chem. 2002, 45, 3327-3330
36. Kagechika, H.; Kawachi, E.; Hashimoto, Y.; Himi, T.; Shudo, K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity J. Med. Chem. 1988, 31, 2182-2192
37. Miwako, I.; Kagechika, H. Tamibarotene Drugs Today 2007, 43, 563-568
38. Kasuga, J.; Oyama, T.; Hirakawa, Y.; Makishima, M.; Morikawa, K.; Hashimoto, Y.; Miyachi, H. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part Bioorg. Med. Chem. Lett. 2008, 18, 4525-4528
39. Aoyama, A.; Aoyama, H.; Dodo, K.; Makishima, M.; Hashimoto, Y.; Miyachi, H. LXR antagonists with a 5-substituted phenanthridin-6-one skeleton: synthesis and LXR transrepression activities of conformationally restricted carba-T0901317 analogs Heterocycles 2008, 76, 137-142
40. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility J. Comput. Chem. 2009, 30, 2785-2791
41. Boerma, L. J.; Xia, G.; Qui, C.; Cox, B. D.; Chalmers, M. J.; Smith, C. D.; Lobo-Ruppert, S.; Griffin, P. R.; Muccio, D. D.; Renfrow, M. B. Defining the communication between agonist and coactivator binding in the retinoid X receptor ? ligand binding domain J. Biol. Chem. 2014, 289, 814-826
42. Arakawa, K.; Ishihara, T.; Aoto, M.; Inamasu, M.; Saito, A.; Ikezawa, K. Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells Br. J. Pharmacol. 1998, 125, 429-436
43. Wagner, C. E.; Jurutka, P. W.; Marshall, P. A.; Groy, T. L.; van der Vaart, A.; Ziller, J. W.; Furmick, J. K.; Graeber, M. E.; Matro, E.; Miguel, B. V.; Tran, I. T.; Kwon, J.; Tedeschi, J. N.; Moosavi, S.; Danishyar, A.; Philp, J. S.; Khamees, R. O.; Jackson, J. N.; Grupe, D. K.; Badshah, S. L.; Hart, J. W. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene) J. Med. Chem. 2009, 52, 5950-5966
44. Kain, S. R. Use of secreted alkaline phosphatase as a reporter of gene expression in mammalian cells Methods Mol. Biol. 1997, 63, 49-60
45. Landy, A. Dynamic, structural, and regulatory aspects of lambda site-specific recombination Annu. Rev. Biochem. 1989, 58, 913-949
46. Walhout, A. J.; Temple, G. F.; Brasch, M. A.; Hartley, J. L.; Lorson, M. A.; van den Heuvel, S.; Vidal, M. GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes Methods Enzymol. 2000, 328, 575-592
47. Liang, F.; Matrubutham, U.; Parvizi, B.; Yen, J.; Duan, D.; Mirchandani, J.; Hashima, S.; Nguyen, U.; Ubil, E.; Loewenheim, J.; Yu, X.; Sipes, S.; Williams, W.; Wang, L.; Bennett, R.; Carrino, J. ORFDB: an information resource linking scientific content to a high-quality open reading frame (ORF) collection Nucleic Acids Res. 2004, 32, D595-D599
48. Hengen, P. Purification of His-Tag fusion proteins from Escherichia coli Trends Biochem. Sci. 1995, 20, 285-286
49. Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography Acta. Crystallogr.; Sect. D: Biol. Crystallogr. 1994, 50, 760-763
50. Maron, D. M.; Ames, B. N. Revised methods for the Salmonella mutagenicity test Mutat. Res. 1983, 113, 173-215
51. Safety Guidelines; International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): Geneva, 2014; http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html.